The ARCADIA study was a multicenter, double-blind, randomized clinical trial conducted between 2017 and 2020.
The University of New Mexico Comprehensive Cancer Center has successfully received reaccreditation from the Commission on Cancer (CoC), a quality program of the American College of Surgeons. The ACS CoC is a consortium of professional organizations dedicated to improving survival and quality of life for patients with cancer by setting and raising standards.
Highlights research work being down across several disciplines at the veterinary school
Topically applied products containing human platelet extract or vitamin C provide similar improvements in age spots (photoaging) of the hands, as reported in a clinical trial within the November issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). The journal is published in the Lippincott portfolio by Wolters Kluwer.
New Jersey Gov. Phil Murphy joined Rutgers and community leaders on Oct. 30 at the Child Health Institute in New Brunswick to celebrate a $47.5 million federal grant for the Rutgers Institute for Translational Medicine and Science that will improve health and well-being for New Jersey residents over the next seven years.
The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularization.
Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary arteries.
Most patients should continue taking their glucagon-like peptide-1 (GLP-1) receptor agonists before elective surgery, suggests new clinical guidance released by the American Society of Anesthesiologists (ASA), American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons. Patients at the highest risk for significant gastrointestinal (GI) side effects should follow a liquid diet for 24 hours before the procedure or other measures, depending on the specific circumstances.
First-of-its kind work led by Mount Sinai researcher supports reserving this technique for extreme cases
A global study of a combination drug therapy, led by an investigator at Huntsman Cancer Institute, has shown improved overall survival rates for metastatic prostate cancer compared to standard treatments.
A syndrome called cachexia, which triggers unexplained loss of weight and muscle mass, causes severe illness and death among patients with cancer and other serious health conditions.
A new international trial is investigating the efficacy and safety of gene therapy in patients with Hurler syndrome and will compare results of gene therapy against BMT which is the current standard of care. UCSF Benioff Children’s Hospitals are among three sites in the U.S. and seven in the world now enrolling patients for the clinical trial.
This year’s lectures highlight time and process management for physicians, leveraging networks for clinical research, innovations in endoscopy, kindness-influenced trust and healing, and personal and professional opportunities in Africa.
Gastroenterologists and other GI health care professionals will convene at the Pennsylvania Convention Center in Philadelphia, PA, for the premier clinical gastroenterology event—the American College of Gastroenterology’s 89th Annual Scientific Meeting and Postgraduate Course (ACG 2024).
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
